54408-52-5

Usage

Uses

Used in Organic Synthesis:
5-Bromoquinaldine is used as a synthetic intermediate for the production of various complex organic compounds. Its unique structure and reactivity make it a valuable component in the synthesis of a wide range of molecules, contributing to the development of new materials and pharmaceuticals.
Used in Pharmaceutical Industry:
5-Bromoquinaldine is used as a building block in the synthesis of certain pharmaceutical compounds. Its presence in the molecular structure can impart specific properties to the final product, such as improved efficacy or reduced side effects, making it an important tool in drug development.
Used in Chemical Research:
5-Bromoquinaldine is used as a research compound in the study of chemical reactions and mechanisms. Its reactivity and structural features provide insights into the behavior of similar compounds, aiding in the understanding of organic chemistry and the design of new synthetic pathways.
Safety Considerations:
While 5-Bromoquinaldine is not typically dangerous under normal handling procedures, direct contact with the compound may potentially cause skin and eye irritation. Therefore, it is essential to follow proper safety protocols and use appropriate protective equipment when working with this substance.

Upstream product

• 57155-51-8 2-Methyl-quinoline-5-diazonium; bromide 
• 54408-50-3 2-methyl-5-aminoquinoline 
• 91-63-4 2-methylquinoline 
• 591-19-5 m-Bromoaniline 
• 123-63-7 paracetaldehyde 
• 23877-94-3 2-methyl-5-nitroquinoline 

Downstream Products

• 79205-04-2 5-methoxy-2-methylquinoline 
• 91-63-4 2-methylquinoline 
• 1362021-86-0 2-methyl-5-styryl-1,2,3,4-tetrahydroquinoline 

Relevant academic research and scientific papers

WDR5 INHIBITORS AND MODULATORS

Isoquinolmone compounds and derivatives inhibit WDR5 and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.

Catalytic hydrogenation with frustrated lewis pairs: Selectivity achieved by size-exclusion design of lewis acids

Catalytic hydrogenation that utilizes frustrated Lewis pair (FLP) catalysts is a subject of growing interest because such catalysts offer a unique opportunity for the development of transition-metal-free hydrogenations. The aim of our recent efforts is to further increase the functional-group tolerance and chemoselectivity of FLP catalysts by means of size-exclusion catalyst design. Given that hydrogen molecule is the smallest molecule, our modified Lewis acids feature a highly shielded boron center that still allows the cleavage of the hydrogen but avoids undesirable FLP reactivity by simple physical constraint. As a result, greater latitude in substrate scope can be achieved, as exemplified by the chemoselective reduction of α,β-unsaturated imines, ketones, and quinolines. In addition to synthetic aspects, detailed NMR spectroscopic, DFT, and 2H isotopic labeling studies were performed to gain further mechanistic insight into FLP hydrogenation. Copyright

X-RAY AND GAMMA-PHOTON ACTIVABLE ORGANIC COMPOUNDS, THEIR PREPARATION AND THEIR USES

The present invention relates to a X-ray and gamma-photon activable compound responding to the following formula (I). The present invention also relates to methods of synthesizing a compound according to the invention, and to an aqueous or physiological solution comprising at least one compound of the invention. The present invention also concerns a method of liberating a biologically active compound, said method involving the step of irradiating at least one compound, or at least one aqueous or physiological solution according to the invention. Finally, the present invention relates to a pharmaceutical composition comprising at least one compound, or at least one aqueous or physiological solution according to the invention.

Novel 5-HT1A/1B/1D receptors antagonists with potent 5-HT reuptake inhibitory activity

Novel 2-methyl-5-quinolinyl-1-piperazinylalkyl-3,4-dihydro-2H-1,4-benzoxazin-3-ones showing high affinities for the 5-HT1A/1B/1D receptors coupled with potent 5-HT reuptake inhibitory activity have been discovered. This is the first report desc